These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 25512118

  • 1. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P, Molik M, Foltynski P.
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C, Pitt M, Moxham T, Stein K.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [Abstract] [Full Text] [Related]

  • 6. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
    Michallet AS, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, Salles G, Coiffier B, Laurent G, Ysebaert L.
    J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
    Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner CM, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stilgenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K.
    Leuk Lymphoma; 2013 Aug; 54(8):1821-2. PubMed ID: 23631654
    [Abstract] [Full Text] [Related]

  • 11. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA, da Silva AS, Souza KM, Koury Cde N, de Mello LM.
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
    Blommestein HM, de Groot S, Aarts MJ, Vemer P, de Vries R, van Abeelen AF, Posthuma EF, Uyl-de Groot CA.
    Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
    [Abstract] [Full Text] [Related]

  • 14. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
    Casado LF, García Marco JA, Gilsanz F, González M, Ríos E, de la Serna J, Urbano A, Vicente V, Rubio-Terrés C, Castro AJ.
    Gac Sanit; 2011 Nov; 25(4):274-81. PubMed ID: 21664727
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
    Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, Hartmann H, Marschner N.
    Hematol Oncol; 2015 Mar; 33(1):15-22. PubMed ID: 24733536
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG.
    Appl Health Econ Health Policy; 2017 Aug; 15(4):501-512. PubMed ID: 28342061
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P.
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.